We are live on !
Find out more
HighMark Wealth Management Portfolio holdings
AUM
$299M
Turnover
13.67%
1-Year Est. Return
53.01%
This Fund
S&P 500
This Quarter Est. Return
+21.77%
1 Year Est. Return
+53.01%
3 Year Est. Return
+109.68%
5 Year Est. Return
+113.63%
10 Year Est. Return
–
AUM
$299M
AUM Growth
+$52.9M
(+22%)
Cap. Flow
+$8.26M
Cap. Flow % of AUM
Cap. Flow %
2.77%
Top 10 Holdings %
Top 10 Hldgs %
65.82%
Holding
600
New
46
Increased
156
Reduced
94
Closed
36
Avg Time Held
Equity + Options
3.4
years
Top 10 Avg Time Held
Equity + Options
2.7
years
Top 20 Avg Time Held
Equity + Options
2.3
years
Avg Time Held Equity only
3.4
years
Top 10 Avg Time Held Equity only
2.7
years
Top 20 Avg Time Held Equity only
2.3
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Fidelity MSCI Health Care Index ETF
FHLC
|
+$18.3M |
| 2 |
SI-BONE Inc
SIBN
|
+$3.79M |
| 3 |
Duos Technologies
DUOT
|
+$2.91M |
| 4 |
Apogee Therapeutics
APGE
|
+$2.91M |
| 5 |
Neuropace
NPCE
|
+$1.61M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
CNTA
Centessa Pharmaceuticals
CNTA
|
+$9.41M |
| 2 |
iShares Core S&P 500 ETF
IVV
|
+$5.14M |
| 3 |
AnaptysBio
ANAB
|
+$3.29M |
| 4 |
iShares MSCI EAFE Value ETF
EFV
|
+$1.64M |
| 5 |
Piper Sandler
PIPR
|
+$1.27M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Miscellaneous | 64.9% |
| 2 | Healthcare | 21.84% |
| 3 | Technology | 4.77% |
| 4 | Financials | 3.58% |
| 5 | Industrials | 1.3% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
376
Altimmune
ALT
$393M
| $6.08K | ﹤0.01% |
2,000
| – | – |
2025 Q4
2 quarters
|
|
377
Fidelity Disruptive Technology ETF
FDTX
$278M
| $6.08K | ﹤0.01% |
105
| – | – |
2025 Q2
4 quarters
|
|
378
TJX Companies
TJX
$155B
| $6.06K | ﹤0.01% |
40
-23
| -37% | -$3.64K |
2023 Q4
10 quarters
|
|
379
Ingersoll Rand
IR
$31.8B
| $5.98K | ﹤0.01% |
73
| – | – |
2024 Q4
6 quarters
|
|
380
Intuitive Surgical
ISRG
$154B
| $5.96K | ﹤0.01% |
40
+25
| +167% | +$10.9K |
2022 Q4
14 quarters
|
|
381
Banco Santander
SAN
$165B
| $5.87K | ﹤0.01% |
425
-60
| -12% | -$744 |
2026 Q1
1 quarter
|
|
382
Rocket Companies
RKT
$39.1B
| $5.78K | ﹤0.01% |
367
+201
| +121% | +$2.9K |
2026 Q1
1 quarter
|
|
383
Shell
SHEL
$298B
| $5.76K | ﹤0.01% |
74
-9
| -11% | -$777 |
2026 Q1
1 quarter
|
|
384
Verizon
VZ
$187B
| $5.51K | ﹤0.01% |
130
+1
| +0.8% | +$47 |
2019 Q4
26 quarters
|
|
385
Okta
OKTA
$32.3B
| $5.46K | ﹤0.01% |
40
-10
| -20% | -$940 |
2026 Q1
1 quarter
|
|
386
Wabtec
WAB
$48.4B
| $5.4K | ﹤0.01% |
20
| – | – |
2019 Q4
26 quarters
|
|
387
Hinge Health
HNGE
$9.32B
| $5.4K | ﹤0.01% |
65
| – | – |
2026 Q1
1 quarter
|
|
388
Shopify
SHOP
$201B
| $5.37K | ﹤0.01% |
47
-1
| -2% | -$114 |
2022 Q2
16 quarters
|
|
389
Fidelity MSCI Consumer Staples Index ETF
FSTA
$1.55B
| $5.25K | ﹤0.01% |
100
| – | – |
2024 Q4
6 quarters
|
|
390
Mitsubishi UFJ Financial
MUFG
$241B
| $5.07K | ﹤0.01% |
255
-113
| -31% | -$2.13K |
2024 Q1
9 quarters
|
|
391
Moody's
MCO
$87.3B
| $4.98K | ﹤0.01% |
11
| – | – |
2023 Q2
12 quarters
|
|
392
AstraZeneca
AZN
$289B
| $4.97K | ﹤0.01% |
26
-3
| -10% | -$564 |
2022 Q3
15 quarters
|
|
393
Baron First Principles ETF
RONB
$371M
| $4.88K | ﹤0.01% |
+200
| New | +$4.72K |
2026 Q2
0 quarters
|
|
394
Xencor
XNCR
$2.21B
| $4.83K | ﹤0.01% |
300
| – | – |
2019 Q4
26 quarters
|
|
395
Texas Instruments
TXN
$276B
| $4.77K | ﹤0.01% |
+16
| New | +$4.44K |
2026 Q2
0 quarters
|
|
396
Coherent
COHR
$39.4B
| $4.73K | ﹤0.01% |
+12
| New | +$4.24K |
2026 Q2
0 quarters
|
|
397
Vanguard Financials ETF
VFH
$13.6B
| $4.69K | ﹤0.01% |
36
+1
| +3% | +$128 |
2025 Q3
3 quarters
|
|
398
Sempra
SRE
$56.2B
| $4.64K | ﹤0.01% |
+50
| New | +$4.65K |
2026 Q2
0 quarters
|
|
399
TSMC
TSM
$2.07T
| $4.62K | ﹤0.01% |
10
-3
| -23% | -$1.22K |
2025 Q1
5 quarters
|
|
400
Trump Media & Technology Group
DJT
$1.57B
| $4.46K | ﹤0.01% |
577
| – | – |
2021 Q4
18 quarters
|
|
Similar funds
BOC
HighMark Wealth Management's Q2 2026 Portfolio in Review
As of Q2 2026, HighMark Wealth Management held 600 positions worth $299M, up 22% from $246M the previous quarter. Its ten largest holdings account for 66% of the portfolio.
HighMark Wealth Management's Q2 2026 filing shows 46 new, 156 increased, 94 reduced and 36 closed positions. Its largest new stake was Duos Technologies: 289,884 shares worth $3.48M. The largest sale was Centessa Pharmaceuticals, an estimated $9.41M.
By sector, the portfolio is most concentrated in Miscellaneous at 65% of assets, down from 65% a quarter earlier, followed by Healthcare and Technology.
- HighMark Wealth Management's largest Q2 2026 buy was Duos Technologies: 289,884 shares worth $3.48M.
- HighMark Wealth Management added most to Fidelity MSCI Health Care Index ETF in Q2 2026, an estimated $18.3M increase.
- HighMark Wealth Management's biggest Q2 2026 reduction was iShares Core S&P 500 ETF, cutting an estimated $5.14M.
- HighMark Wealth Management fully exited Centessa Pharmaceuticals in Q2 2026, selling an estimated $9.41M.
- HighMark Wealth Management's ten largest holdings make up 66% of its $299M portfolio in Q2 2026.
- HighMark Wealth Management opened 46 new positions and closed 36 in Q2 2026.
- HighMark Wealth Management's portfolio value rose 22% quarter-over-quarter to $299M.
Based on HighMark Wealth Management's 13F filing for Q2 2026, filed 12 Aug 2026.